Figure 1: The IL-1β/IL-1R1 axis promotes tumour growth in diet-induced obese mice.
From: Obesity-associated NLRC4 inflammasome activation drives breast cancer progression
The indicated mice were given either a ND or HFD for 10 weeks, and then the indicated cells were implanted into the #4 mammary gland. See Supplementary Fig. 2b. (a–c) Mice were treated with anti-IL-1R1 antibody or control IgG once tumours were palpable (a,c) or with recombinant IL-1 receptor antagonist (rIL1RA) (b) starting the day of Py8119 cell transplant. Data represent the average tumour volume±s.e.m (a–b: n=5 HFD+IgG, n=5 HFD+anti-IL-1R1, n=5 HFD+anti-IL1RA n=14 ND, n=24 HFD; C: n=5 all groups). (d,e) Data represent the average body weight (d) and Py8119 tumour volume (e) of the indicated mice±s.e.m. (n=5 Il1α−/− ND, n=4 Il1α−/− HFD, n=14 WT ND, n=24 WT HFD). (f,g) Data represent the average body weight (f) and tumour volume (g) of the indicated mice±s.e.m. ((e) n=5 Il1β−/− ND, n=5 Il1β−/− HFD, n=14 WT ND, n=24 WT HFD; f: n=1 Il1β−/− ND, n=2 Il1β−/− HFD). Only mice that had measurable tumours after 5 weeks are represented in g. Two-way ANOVA was used to determine significance. All tumour studies were repeated in a different cohort of animals.
